These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 10210764)
1. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. Mabro M; Granisétron PK Bull Cancer; 1999 Mar; 86(3):295-301. PubMed ID: 10210764 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429 [TBL] [Abstract][Full Text] [Related]
3. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147 [TBL] [Abstract][Full Text] [Related]
4. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047 [TBL] [Abstract][Full Text] [Related]
5. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma. Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311 [TBL] [Abstract][Full Text] [Related]
6. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505 [TBL] [Abstract][Full Text] [Related]
8. The use of oral granisetron versus intravenous ondansetron for antiemetic prophylaxis in patients undergoing laparoscopic surgery: the effect on emetic symptoms and quality of recovery. White PF; Tang J; Hamza MA; Ogunnaike B; Lo M; Wender RH; Naruse R; Sloninsky A; Kariger R; Cunneen S; Khalili T Anesth Analg; 2006 May; 102(5):1387-93. PubMed ID: 16632815 [TBL] [Abstract][Full Text] [Related]
9. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683 [TBL] [Abstract][Full Text] [Related]
10. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron]. Coiffier B; Khayat D; Misset JL; Votan B Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181 [TBL] [Abstract][Full Text] [Related]
11. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710 [TBL] [Abstract][Full Text] [Related]
12. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F; Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346 [TBL] [Abstract][Full Text] [Related]
13. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464 [TBL] [Abstract][Full Text] [Related]
14. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174 [TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Hardy J; Daly S; McQuade B; Albertsson M; Chimontsi-Kypriou V; Stathopoulos P; Curtis P Support Care Cancer; 2002 Apr; 10(3):231-6. PubMed ID: 11904788 [TBL] [Abstract][Full Text] [Related]
16. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Aksoylar S; Akman SA; Ozgenç F; Kansoy S Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235 [TBL] [Abstract][Full Text] [Related]
17. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. Lajolo PP; de Camargo B; del Giglio A Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. Shinohara H; Yonekawa H; Machimura T; Furukawa T; Nishihori H; Kurihara N; Urakami H; Nemoto Y Gan To Kagaku Ryoho; 1998 Feb; 25(3):397-402. PubMed ID: 9492834 [TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin. Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066 [TBL] [Abstract][Full Text] [Related]
20. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin]. Tanimura S; Banba J; Tomoyasu H; Masaki M Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]